Mode
Text Size
Log in / Sign up
N/A N=123 Randomized Treatment

Contingency Management of Alcohol Abuse in the Severely Mentally ILL

Alcohol Abuse · Schizophrenia · Bipolar Disorder · Major Depressive Disorder

Enrolled (actual)
123
Serious AEs
0.0%
Results posted
Jan 2017
Primary outcome: Primary: Alcohol Use as Assessed by Ethyl Glucuronide Detection in Urine — 408.86; 734.79 EtG Value (nanograms per milileter)

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Contingency Management (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Washington
Primary completion
Feb 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Alcohol Use as Assessed by Ethyl Glucuronide Detection in Urine
408.86; 734.79
SECONDARY
Change in Intensive Outpatient Substance Abuse Treatment Attendance
57; 53
SECONDARY
Self Report Drug Use
SECONDARY
Other Drug Use as Measured by Urinalysis
SECONDARY
Community Outcomes
SECONDARY
Psychiatric Symptomology

Summary

The investigators will evaluate the efficacy of a comprehensive 12-week contingency management intervention for treating alcohol dependence for persons with severe mental illness who are seen within the context of a community mental health center setting. The primary contingency will be submission of alcohol-free urines. Additional reinforcers will be provided for intensive outpatient addiction treatment attendance. Reinforcers will be vouchers or actual items useful for day-to-day living. Participants will be 120 adults diagnosed with alcohol dependance and severe mental illness.

Eligibility Criteria

Inclusion Criteria

  • Currently receiving psychiatric [AND intensive outpatient addiction treatment] at Community Psychiatric Clinic (CPC).
  • Aged 18 to 65 years.
  • Ability to understand written and spoken English language.
  • DSM-IV diagnosis of alcohol dependence as assessed by the MINI psychiatric interview.
  • Diagnosis of current serious mental illness: schizophrenia, schizoaffective disorders, bipolar disorder I or II, or recurring major depressive disorders as assessed by the MINI psychiatric interview.
  • Alcohol use in the month prior to study entry: self-reported alcohol use of 5 days or more during the 30 days prior to study entry (5 drinking days/month is selected based on previous research reporting alcohol use in 18% of days assessed in a sample of psychiatric outpatients with co-occurring SUDs & SMI).120
  • A CPC treating clinician must affirm the potential participant is safe to participate in the study.

Exclusion Criteria

  • A significant risk of dangerous alcohol withdrawal: a history of alcohol detoxification or seizure in the last 12 months AND participant or clinician concern that abstinence will induce dangerous alcohol withdrawal.
  • DSM-IV diagnosis of current (last year) drug dependence as assessed by the MINI interview.
  • Any medical/psychiatric condition, or severity of that condition, that in the opinion of the PI, would compromise safe study participation.
  • Chart defined organic brain disorder or dementia.
  • Inability to provide informed consent as measured by the University of California San Diego Brief Assessment of Capacity to Consent (UBACC), a tool designed to screen for ability to provide informed consent for research. If indicated by the UBACC screening process, the more comprehensive MacCAT-CR will be used.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01567943). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search